Embecta (NASDAQ:EMBC) Receives Buy Rating from BTIG Research

BTIG Research reaffirmed their buy rating on shares of Embecta (NASDAQ:EMBC) in a report issued on Friday,Benzinga reports. BTIG Research currently has a $25.00 price objective on the stock.

Other analysts have also recently issued research reports about the stock. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 27th. Weiss Ratings restated a “hold (c-)” rating on shares of Embecta in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $18.50.

Embecta Stock Performance

NASDAQ:EMBC opened at $10.86 on Friday. The company has a market capitalization of $643.02 million, a P/E ratio of 4.58 and a beta of 1.11. The stock’s 50 day moving average price is $11.76 and its 200 day moving average price is $12.96. Embecta has a 52 week low of $9.20 and a 52 week high of $18.07.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.04. Embecta had a negative return on equity of 26.66% and a net margin of 12.92%.The business had revenue of $261.20 million for the quarter, compared to the consensus estimate of $258.07 million. During the same period last year, the business earned $0.65 EPS. The firm’s revenue was down .3% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. As a group, sell-side analysts forecast that Embecta will post 2.85 earnings per share for the current fiscal year.

Embecta Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 17th. Shareholders of record on Friday, February 27th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Friday, February 27th. This represents a $0.60 dividend on an annualized basis and a yield of 5.5%. Embecta’s dividend payout ratio (DPR) is presently 36.81%.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its position in Embecta by 9.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,708 shares of the company’s stock valued at $148,000 after buying an additional 1,050 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Embecta by 7.9% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,005 shares of the company’s stock worth $145,000 after acquiring an additional 1,093 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Embecta by 5.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,589 shares of the company’s stock worth $209,000 after acquiring an additional 1,110 shares in the last quarter. CWM LLC raised its holdings in shares of Embecta by 16.0% in the second quarter. CWM LLC now owns 8,080 shares of the company’s stock valued at $78,000 after purchasing an additional 1,115 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Embecta by 2.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,323 shares of the company’s stock worth $629,000 after purchasing an additional 1,159 shares in the last quarter. Institutional investors and hedge funds own 93.83% of the company’s stock.

Key Stories Impacting Embecta

Here are the key news stories impacting Embecta this week:

• Positive Sentiment: Q1 results beat expectations — EPS $0.71 vs. $0.67 consensus and revenue $261.2M vs. $258.1M; management provided slide deck and press release that highlight execution on core products. Embecta Q1 Results
• Positive Sentiment: BTIG reaffirmed a Buy and set a $25 price target (material upside vs. current levels), which can boost investor sentiment and momentum. BTIG Reaffirmation
• Positive Sentiment: Board declared a quarterly cash dividend of $0.15/share (annualized yield ~5.7%) — supports income-focused investors and may attract yield-seeking flows. Dividend Announcement
• Neutral Sentiment: Earnings call materials and transcripts are available (slides, call transcript, presentation) for investors wanting detail on product trends, margin drivers and regional performance; these provide transparency but no new catalyst by themselves. Earnings Presentation
• Negative Sentiment: FY2026 EPS guidance of $2.80–3.00 is modestly below sell‑side consensus (~$2.89), which could cap upside as investors weigh near-term growth headwinds vs. one-time execution positives. Guidance Details

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.